[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy-in-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy-in-diabetic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,51,76,106,136,160,190,212,242],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100490156","successfully-achieving-and-maintaining-euglycemia-during-pregnancy-for-type-2-diabetes-through-technology-and-coaching-100490156",false,"NCT05662462","Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching","ACHIEVE: Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching","Inclusion Criteria:\n\n1. pregnant individuals age ≥18 years;\n2. ≤20 weeks of gestation (specifically, \\\u003C20+6 weeks);\n3. diagnosis of pregestational T2D and A1c ≥6.5% at the time of study enrollment;\n4. Medicaid insurance;\n5. English or Spanish speaking;\n6. cognitively able to complete the study requirements;\n7. consent to all study activities;\n8. accessible for participation in study activities;\n9. use a smartphone with internet access;\n\nParticipants must also consent to the study team abstracting information from their electronic health records (EHRs), using CGM for glucose monitoring if randomized to the intervention group, tracking the participants' clinic, hospital, and emergency room visits during the study period, as well as tracking the number of times the participants use the ACHIEVE mobile health (mHealth) application (app), including what activities are used in the mobile application (e.g., recording blood glucose, scheduling appointments, messaging their healthcare providers, accessing educational resources).","FEMALE","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ACHIEVE RCT will measure the effect of the intervention (mHealth app with CGM, provider dashboard, and care team coaching) compared to current standard care (prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist) on achieving glycemic control (hemoglobin A1c \\\u003C6.5% in the third trimester). We hypothesize a 25% absolute increase in the proportion of participants in the intervention group who will meet the target hemoglobin A1c \\\u003C6.5% in the third trimester compared to the standard care group",[26,27,28,29],"Pre-Gestational Diabetes","Type2diabetes","Pregnancy in Diabetic","Pregnancy, High Risk",[31,32,33,34,35,36,37],"mHealth","Pregnancy","Type 2 diabetes","Continuous glucose monitoring","Mobile application","Medicaid","Glycemic control","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-29","ACTUAL",{"date":44,"type":42},"2024-07-11",{"date":46,"type":20},"2029-03",{"name":48,"class":49},"Ohio State University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100592347","characterization-of-placental-diffusion-100592347","NCT06992245","Characterization of Placental Diffusion","Characterization of Placental Diffusion in Women With Diabetes Using DW-MRI","Inclusion Criteria:\n\n* Women with PGAM (Pre-gestational diabetes) diagnosed before 20 weeks of pregnancy\n* Women with GDMA (Gestational diabetes) diagnosed by OGTT after 20 weeks of pregnancy\n\nExclusion Criteria:\n\n* pregnant women with placental hypoxia disease related in the past\n* pregnant women with placental hypoxia disease related in the present\n* non-singleton pregnancy\n* women in active labor or rupture of membrane\n* smoking women\n* suspicion of placenta accreta",true,"50 Years",{"count":61,"type":20},40,[23],"DW-MRI Allows a quantitative comparison of diffusion as an expression of tissue hypoxia. The investigators aim is to compare changes in placental diffusion in pregnant women with uncontrolled diabetes compared to healthy pregnant women using DW-MRI.\n\nThe investigators hypothesize that placentas of diabetic mothers will show lower diffusion \u002F perfusion compared to placentas of healthy women.",[28,65],"Placenta Diseases","2025-12-18",{"date":68,"type":42},"2025-12-24",{"date":70,"type":42},"2023-07-06",{"date":72,"type":20},"2027-12",{"name":74,"class":75},"Hillel Yaffe Medical Center","OTHER_GOV",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100542523","noninvasive-evaluation-of-fetal-hyperinsulinemia-with-ultrasound-radiomics-100542523","NCT06343974","Noninvasive Evaluation of Fetal Hyperinsulinemia With Ultrasound Radiomics","Inclusion Criteria:\n\n* Age between 18-45 years\n* Capable to give an informed consent\n* Singleton pregnancy\n* Planning to deliver in Turku University Hospital\n* Maternal BMI \\\u003C 40\n* Gestational age should be confirmed by first trimester ultrasound\n* Normal oral glucose tolerance test (OGTT) at 24-28 gestational weeks in controls\n\nExclusion Criteria:\n\n* Major fetal chromosomal, genetic, or structural anomaly\n* Fetal growth restriction, or birth weight \\\u003C 10th centile\n* Birth weight \\> 90th centile or polyhydramnios in the controls\n* Non-reassuring fetal status requiring immediate treatment, or intrauterine fetal demise\n* Verified fetal infection (e.g. cytomegalovirus, toxoplasma, hepatitis B and C), excluding bacterial infection due to intrapartum chorioamnionitis\n* Placenta accreta spectrum disorder\n* Major maternal medical condition requiring systemic pharmacological treatment, other than non-severe hypertension, hypothyroidism, asthma, mild psychiatric disorders, etc.\n* Alcohol or tobacco use, or substance abuse in pregnancy","45 Years",{"count":84,"type":20},60,"OBSERVATIONAL","The goal of this observational study is to compare fetal liver ultrasound radiomics between pregnancies complicated by type 1 diabetes and healthy controls.\n\nThe main questions it aims to answer are:\n\n* Are fetal liver ultrasound radiomic features reproducible?\n* Does fetal liver ultrasound radiomics differ between pregnancies complicated by type 1 diabetes and healthy controls?\n\nParticipants will undergo ultrasound examination to collect ultrasound data for the analyses.",[28,88],"Diabetes Mellitus, Type 1",[90,91,92,93,94,95],"ultrasonography","fetus","radiomics","hyperinsulinemia","liver","pregnancy","2025-11-23",{"date":98,"type":42},"2025-11-28",{"date":100,"type":42},"2024-10-11",{"date":102,"type":20},"2026-06-01",{"name":104,"class":75},"Turku University Hospital",2,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":50},"100509101","a-randomized-controlled-trial-of-diabetes-screening-immediately-postpartum-dip-and-follow-up-pp-care-100509101","NCT05909046","A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE","A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) - Follow up Study: Patient Perspectives on Postpartum Interventions to Improve Future Maternal CARdiovascular hEalth After Gestational Diabetes (PP CARE)","DIP - Inclusion Criteria:\n\n* Immediately postpartum individuals during their delivery hospital admission\n* ≥ 18 years old with the ability to give informed consent.\n* Diagnosed with GDM during pregnancy by:\n\n  * Elevated one-hour 50-gram glucose challenge test any time during pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis OR\n  * Two elevated values on a 3-hour 100-gram glucose tolerance test any time in pregnancy AND provider documentation of gestational diabetes (NOT pregestational diabetes) diagnosis\n* English or Spanish speaking\n* Receiving prenatal and postpartum care at OSU\n\nDIP- Exclusion Criteria:\n\n* Individuals who cannot tolerate a 2-hour oral glucose tolerance test (OGTT) (i.e. history of gastric bypass)\n* Not English or Spanish speaking\n\nPP CARE Inclusion criteria: Enrolled DIP participants who are English speaking will be eligible for PP CARE follow up if they are between 12 and 24 months postpartum.\n\nPP CARE Exclusion criteria: Spanish speaking DIP participants will be excluded because the study team does not include anyone who is Spanish speaking.",{"count":114,"type":20},104,[23],"DIP : To conduct a pragmatic, non-blinded randomized controlled trial (pRCT) of immediate in-patient postpartum OGTT prior to delivery discharge (intervention) versus 4-12 week outpatient postpartum OGTT (current standard care) to improve the frequency of post-partum diabetes screening among individuals with a pregnancy complicated by GDM.\n\nFollow up PP CARE: To engage with individuals with a history of GDM through a patient-centered mixed-methods survey and qualitative assessment to evaluate the barriers to and facilitators of Cardiovascular health (CVH) counseling and risk-reduction postpartum at the patient and healthcare system levels inclusive of Social determinants of health (SDOH) and structural factors, as well as patient preferences and perspectives on CVH and wellness interventions",[26,27,28,29,118,119],"Gestational Diabetes","Gestational Diabetes Mellitus in the Puerperium",[121,32,122,123,124,125,126,127],"2-hour oral glucose tolerance test (OGTT)","diabetes mellitus screening","postpartum","cardiometabolic health","cardiovascular health","type 2 diabetes","prediabetes","2025-11-19",{"date":130,"type":42},"2025-11-24",{"date":132,"type":42},"2023-07-24",{"date":134,"type":20},"2026-06-30",{"name":48,"class":49},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":50},"100538509","gestational-diabetes-after-gastric-bypass-surgery-100538509","NCT06291766","Gestational Diabetes After Gastric Bypass Surgery","The Impact of Continous Glucose Monitoring on Pregnancy Outcome, in Women With Gestational Diabetes and a History of Gastric Bypass Surgery.","Inclusion Criteria:\n\n* Understands written and spoken Swedish\n* Previous Gastric Bypass surgery\n* Diagnosed with gestational diabetes according to our local criteria\n* Planned follow up at the Specialized Maternity Ward at Skane University Hospital\n* Understands the use of CGM and is willing to use the system\n* Have signed informed consent\n\nExclusion Criteria:\n\n* Other kinds of bariatric surgery",{"count":144,"type":20},120,[23],"The goal of this trial is to compare different means of glucose monitoring in women with gestational diabetes and a history of gastric bypass surgery.\n\nThe main question it aims to answer is:\n\nHow does continous glucose monitoring impact the treatment and affect pregnancy outcome in these women.\n\nParticipants will be randomized to either continous glucose monitoring or regular capillary glucose measurements during the last trimester of their pregnancy. Researchers will compare the glucose measurement outcomes, the glucose lowering treatment given and pregnancy outcomes between groups.",[148,149,28,150],"Diabetes, Gestational","Gastric Bypass Status for Obesity Complicating Pregnancy, Childbirth, or the Puerperium","Blood Glucose Self Monitoring","2025-08-18",{"date":153,"type":42},"2025-08-22",{"date":155,"type":42},"2024-01-01",{"date":157,"type":20},"2035-12",{"name":159,"class":49},"Region Skane",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":58,"sex":167,"minAge":17,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":85,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100491393","danish-diabetes-birth-registry-2-100491393","NCT05678543","Danish Diabetes Birth Registry 2","DDBR2","Inclusion Criteria:\n\n* Women, age ≥ 18 years\n* Type 1 diabetes, type 2 diabetes or other types of pre-existing diabetes (e.g., maturity onset diabetes of the young (MODY))\n* Partners of women fulfilling these inclusion criteria, age ≥ 18 years\n* Offspring of women fulfilling these inclusion criteria\n\nExclusion Criteria:\n\n* No proficiency in Danish or English to understand oral and written information","ALL",{"count":169,"type":20},2500,"10 Months","Pregnancies in women with pre-existing diabetes are considered \"high risk\" pregnancies, poses daily clinical challenges and in terms of research - a number of unanswered questions. Therefore, the investigators wish to establish a nationwide cohort of pregnancies complicated by pre-existing diabetes - the Danish Diabetes Birth Registry (DDBR2) The DDBR2 registry comprises all types of pre-existing diabetes including T1D, T2D and other types (as MODY), generating a nationwide cohort of mother\u002Fpartner\u002Fchildren trios with accessible registry-, clinical data and biological biobank samples. This will enable the investigators to use data longitudinally to examine short- and long-term outcomes of pregnancies in women with diabetes.",[28,173,174,175,176,177,178,179],"Type 1 Diabetes","Type 2 Diabetes","Parents","Fetal Complications","Maternal Diabetes","Birth Injuries","Family","2024-04-11",{"date":182,"type":42},"2024-04-12",{"date":184,"type":42},"2023-01-01",{"date":186,"type":20},"2030-12-31",{"name":188,"class":49},"Odense University Hospital",4,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":58,"sex":167,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":189},"100526952","prenatal-and-obstetric-maternal-exposures-and-islet-autoantibodies-in-early-life-100526952","NCT06141434","PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life","PROMISE","Inclusion Criteria:\n\n* Pregnant women and their offspring where the offspring has a first degree relative (mother, biological father, full sibling) with type 1 diabetes\n* Mother is 18 or older\n* Mother is both gestational and biological mother\n* Gestation up to 24 weeks at enrollment\n\nExclusion Criteria:\n\n* Parents do not agree to inclusion of the offspring in the study and genetic risk testing\n* Greater than singleton pregnancy","0 Days","99 Years",{"count":200,"type":20},6000,"This research study is called 'PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life: The PROMISE Study'. The purpose of this study is to find out more about how exposures during pregnancy, such as having an infection, diet and growth may impact later risk of type 1 diabetes (TID) and islet autoimmunity in the child. We are also interested in finding out more about why having a father or sibling with T1D increases risk of autoimmunity in the child more than having a mother with T1D.\n\nWe are enrolling women who are pregnant and either have T1D or another first degree relative (father or full sibling) of the baby has T1D. The biological father is also invited to enroll in study, as it is important to understand how the father's health and genetics may contribute to the child's risk of developing T1D. The study procedures for the mother, father and baby are explained below.\n\nMother: Pregnant women will be asked to complete a visit once per trimester (3 visits) during pregnancy and one visit up to 12 weeks after delivery. At each visit, mothers will consent to a blood draw, collection of biological samples and the completion of questionnaires. . Mothers who have T1D will also be asked to download any diabetes device data they have, such as continuous glucose monitor or insulin pump data.\n\nFather: The (biological) father will be invited to enroll in a single visit. He will consent to a blood draw and completion of questionnaires. Fathers with T1D will also be asked to download any diabetes device data they have, such as continuous glucose monitor or insulin pump data.\n\nBaby: The baby will have blood collected at birth to determine the genetic risk for T1D. Families will consent to the completion of questionnaires about growth, health and diet at 6, 12, 18 and 24 months of age and between 5-7 years of age, and to complete blood testing for islet autoantibodies at 24 months and between 5-7 years of age. For those children with a high genetic risk score, we will also collect blood for autoantibody testing at 6, 12, and 18 months of age.",[173,28],"2023-11-15",{"date":205,"type":42},"2023-11-21",{"date":207,"type":42},"2022-12-01",{"date":209,"type":20},"2032-11-30",{"name":211,"class":49},"University of Colorado, Denver",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":219,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":221,"conditions":222,"keywords":227,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":50},"100497121","effect-of-obesity-diabetes-and-bariatric-surgery-on-pregnancy-outcomes-100497121","NCT05753124","Effect of Obesity, Diabetes and Bariatric Surgery on Pregnancy Outcomes","Investigation and Study of Pregnancy in Overweight or Diabetic Women and the Effect of Bariatric Surgery on Pregnancy Outcomes","Inclusion Criteria:\n\n* Pregnant women with normal size (BMI \\\u003C30)\n* Pregnant women with obesity (BMI ≥30)\n* Pregnant women with glucose disorders\n* Pregnant women with previous bariatric surgery\n\nExclusion Criteria:\n\n* Pregnant women less than 18 years of age\n* Pregnant women with twins\u002Ftriplets",{"count":220,"type":20},700,"The obesity epidemic is growing worldwide and in the UK this is perpetuated with a third of women classified as overweight\u002Fobese in 2020. Many of these woman are of childbearing age and go on to have high risk pregnancies which are often complicated by gestational or pre-existing (type 2 diabetes mellitus (GDM, T2DM). Bariatric surgery is the most successful treatment of sustainable weight loss and is associated with a reduction in rates of GDM, pre-eclampsia, delivery of large babies but increased risk of delivery of small babies and preterm delivery.\n\nThe aims of the study are to investigate the maternal and fetal\u002Fneonatal, biophysical and biochemical, intra-uterine environment and postnatal profile of pregnancies:\n\n1. affected by maternal obesity and\u002For GDM\u002FT2DM compared to pregnancies with normal maternal body mass index (BMI).\n2. with previous maternal bariatric surgery compared to pregnancies without previous bariatric surgery but matched for maternal pre-surgery and early pregnancy BMI.",[223,28,224,225,226],"Obesity","Pregnancy Complications","Pregnancy Related","Bariatric Surgery Status Complicating Pregnancy",[32,228,229,230,231,232],"Gastric sleeve","Gastric bypass","Bariatric surgery","Birth weight","Glucose intolerance","2023-03-01",{"date":235,"type":42},"2023-03-03",{"date":237,"type":42},"2015-05",{"date":239,"type":20},"2027-10",{"name":241,"class":49},"Chelsea and Westminster NHS Foundation Trust",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":50},"100378376","iglucose-remote-patient-monitoring-device-as-an-adjunct-to-routine-glucose-meter-devices-for-glycemic-management-and-control-in-gestational-diabetes-100378376","NCT04206748","iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes","iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes: a Pilot Randomized, Controlled Trial","iGlucose","Inclusion Criteria\n\n* All patients \\>\u002F= women 18 years of age with gestational diabetes or type 2 diabetes during pregnancy and identified by the research team and consented before 30.6 weeks.\n* Non-anomalous singletons\n* Ability to provide informed consent\n\nExclusion Criteria\n\n* Patients with Type 1 diabetes\n* Patients with fetal major congenital abnormalities\n* Patients identified\u002Freferred after 30.6 weeks",{"count":251,"type":20},200,[23],"The purpose of this study is to investigate whether automation of glucose monitoring data to facilitate the total number of recommended and completed SMBG checks improve clinical outcomes for women living with gestational and type 2 diabetes during pregnancy? This is a RCT",[118,255,28],"Type2 Diabetes","2021-09-01",{"date":258,"type":42},"2021-09-02",{"date":260,"type":42},"2019-11-12",{"date":262,"type":20},"2022-11-01",{"name":264,"class":49},"The University of Texas Health Science Center, Houston"]